Coverage with Evidence Development in Bariatric Surgery
CMTP is collaborating with Johns Hopkins University in the development and implementation of a framework that will enable payers to provide reimbursement for all clinical costs (bariatric surgery and weight loss interventions) for patients enrolled in a pilot randomized controlled trial (RCT) of bariatric surgery. We are also assisting JHU in developing an approach to apply this framework to provide coverage for clinical costs for patients that will be enrolled in a national multi-center RCT. In performing this work, CMTP is engaging with payers and other key stakeholders to form a regional alliance to serve as a platform to facilitate not only the JHU trial, but also to set priorities and implement coverage with evidence development (CED) and other strategies to support comparative effectiveness research in obesity and diabetes more generally.
Tirzepatide and semaglutide are FDA-approved for long-term weight management in adults with obesity (or overweight with a weight-related health problem), so some people now have a non-surgical option, though weight often comes back if they stop. In large trials, people taking these medicines lost about 15 to 21 percent of their body weight on average, which is generally less than the loss after gastric bypass or sleeve gastrectomy. Both medicines also lower blood sugar in adults with type 2 diabetes.
For more information on this project, contact Donna Messner.
Sources
- Weight Management Approval: Zepbound label, 2026; Wegovy label, 2026
- Trial Weight Loss: Jastreboff, Tirzepatide Once Weekly for the Treatment of Obesity, New England Journal of Medicine, 2022; Wilding, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021
- Weight Regain: Wilding, Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide, Diabetes, Obesity and Metabolism, 2022; Aronne, Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity, JAMA, 2024
- Bariatric Surgery Weight Loss: Arterburn, Comparative Effectiveness and Safety of Bariatric Procedures for Weight Loss, Annals of Internal Medicine, 2018; Sabatella, Comparative Efficacy of Metabolic/Bariatric Surgery Versus GLP-1 Receptor Agonists, Obesity, 2026
- Blood Sugar: Mounjaro label, 2026; Ozempic label, 2026